Cancer Cell
Volume 18, Issue 1, 13 July 2010, Pages 11-22
Journal home page for Cancer Cell

Article
Integrative Genomic Profiling of Human Prostate Cancer

https://doi.org/10.1016/j.ccr.2010.05.026Get rights and content
Under an Elsevier user license
open archive

Summary

Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in ∼11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.

Highlights

► Integrated genomic profiling of 218 prostate tumors provides a unique public resource ► Androgen receptor coactivator NCOA2 is amplified in primary and metastatic disease ► TMPRSS2-ERG+ tumors associate with 3p14 loss and candidates FOXP1, RYBP, and SHQ1 ► Degree and pattern of CNAs in primary tumors is associated with risk of relapse

CELLCYCLE
HUMDISEASE
DNA

Cited by (0)

8

These authors contributed equally to this work

9

Deceased